Acetylcysteine - AstraZeneca

Drug Profile

Acetylcysteine - AstraZeneca

Alternative Names: Mucomyst; N-acetylcysteine; N-Acetylcysteine - AstraZeneca; NAC; NAC - AstraZeneca

Latest Information Update: 05 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antibronchitics; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis; Dry eyes; Poisoning

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Dec 2002 Launched for Bronchiectasis in Australia (Inhalation)
  • 31 Dec 2002 Launched for Chronic obstructive pulmonary disease in Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top